{"id":17500,"date":"2020-03-06T12:22:28","date_gmt":"2020-03-06T11:22:28","guid":{"rendered":"http:\/\/k2info.w.uib.no\/?p=17500"},"modified":"2020-03-06T12:22:28","modified_gmt":"2020-03-06T11:22:28","slug":"ukens-ansatt-karl-henning-kalland","status":"publish","type":"post","link":"https:\/\/k2info.w.uib.no\/en\/2020\/03\/06\/ukens-ansatt-karl-henning-kalland\/","title":{"rendered":"[:no]Ukens ansatt – Karl-Henning Kalland [:en]This week\u2019s employee – Karl-Henning Kalland [:]"},"content":{"rendered":"

[:no]\"\"<\/a>Kan du fortelle litt om arbeidet ditt? Kva er dei konkrete arbeidsoppg\u00e5vene dine?<\/strong>
\nEg er tilsett i 100 % stilling som professor i medisinsk virologi ved Klinisk institutt 2. I tillegg er eg overlege i bistilling ved Mikrobiologisk avdeling, Haukeland universitetssjukehus. I denne siste stillinga har eg gjennom ei \u00e5rrekke vore engasjert i innf\u00f8ring og bruk av nukleinsyrediagnostikk (t.d. PCR) for raskare og eksakt p\u00e5vising av virusinfeksjonar hos pasientar. Det kliniske og laboratoriearbeidet kjem sv\u00e6rt godt til nytte i virologiundervisninga for medisinstudentane.
\nVed K2 er eg gruppeleiar for \u00abProstate Cancer Therapy Research Group\u00bb. Denne gruppa har ein solid molekyl\u00e6rbiologisk bakgrunn og har forska p\u00e5 grunnleggande reguleringsmekanismar og signalmekanismar i kreftceller og virusinfiserte celler. I l\u00f8pet av dei siste \u00e5ra har innovasjon f\u00e5tt ei st\u00f8rre rolle. Panel av kjemiske stoff er blitt screena for effekt p\u00e5 kreftceller, og vi har oppdaga nye kjemiske stoff og publisert kva for protein stoffa interagerar med i cella og verknadsmekanismar. Patentering p\u00e5g\u00e5r i samarbeid med VIS og med vidare utvikling i samarbeid med forskningsgrupper i Shanghai og firmaet Xennials Therapeutics i Chicago.
\nEit spennande prosjekt er cryoimmunterapien, forkorta CryoIT. Dette er ei form for immunterapi som brukar pasientens eigne dendrittiske immunceller. Etter at deler av kreftvevet er drept ved ein fryseprosess med spesialutstyr inne i pasienten, blir immuncellene injiserte i det frysedrepte kreftvevet. Dei dendrittiske cellene har evne til \u00e5 reagere p\u00e5 det som er forandra i kreftceller og kan deretter instruere heile immunsystemet til angrep p\u00e5 kreftcellene, ogs\u00e5 kreftceller som har spreidd seg i metastaser rundt i kroppen. Ei Fase I klinisk utpr\u00f8ving er nettopp gjennomf\u00f8rt med CryoIT for pasientar med metastatisk prostatakreft. Resultata er sv\u00e6rt nyttige for neste generasjons CryoIT med oppstart i 2021.
\nForskingsgruppa har f\u00e5tt st\u00f8tte fr\u00e5 Forskningsr\u00e5det sitt program NFR BEHANDLING og fr\u00e5 Kreftforeningen for robust produksjon av meir potente terapeutiske dendrittiske celler for neste generasjons CryoIT. Cellene vil bli produserte i det nye terapeutiske cellelaboratoriet i Helse Bergen bygg i Laboratoriebyggets etasje 1M. I dette arbeidet satsar vi p\u00e5 ein synergi mellom det farmakologiske screeningprosjektet og CryoIT.<\/p>\n

Kva likar du \u00e5 arbeide med p\u00e5 K2?<\/b>
\nDet er forskinga som er den store utfordringa og det st\u00f8rste engasjementet, elles ville eg nok ha g\u00e5tt i klinisk retning med pasientarbeid ved sjukehuset. Samarbeidet med dei andre i gruppa og kolleger og kliniske team er inspirerande. Det er ogs\u00e5 givande \u00e5 f\u00e5 undervise og formidle til studentane og erfare dei mange unge talent som er i gang med si utdanning og sine m\u00e5l. Eg opplever at det er eit godt milj\u00f8 i Laboratoriebygget, men at potensialet for forsking og innovasjon er end\u00e5 st\u00f8rre enn det som har manifestert seg til no. Vi har ein kompakt medisinsk campus med sv\u00e6rt godt utstyrte laboratorium. Det er s\u00f8rgeleg at s\u00e5 mange kolleger manglar prosjektfinansiering. Spesielt den eksperimentelle forskinga er underfinansiert etter som driftsutgiftene er relativt h\u00f8ge. Eg er ytterst takksam for den store st\u00f8tten som mi forskingsgruppe har mottatt fr\u00e5 private heidersmenn i Bergen. Den st\u00f8tta har vore essensiell for at v\u00e5re prosjekt no synast i god framdrift, at nye folk er under tilsetting, og at vi ser fram til spennande \u00e5r der ny kreftbehandling er eit hovudm\u00e5l.[:en]\"\"<\/a><\/p>\n

Can you tell us a little about your work? What are your specific tasks?<\/strong><\/p>\n

I am employed in a 100% position as professor of medical virology at the Department of Clinical Science. In addition, I am a senior consultant in the microbiology department, Haukeland University Hospital. In this latter position, I have for many years been involved in the introduction and use of nucleic acid diagnostics (e.g., PCR) for the rapid and accurate detection of viral infections in patients. Clinical and laboratory work is very useful in virology teaching for medical students.
\nAt K2, I am the group leader for the Prostate Cancer Therapy Research Group. This group has a solid molecular biological background and has researched basic regulatory and signaling mechanisms in cancer cells and virus-infected cells. Over the past few years, innovation has become a bigger role. Panels of chemical substances have been screened for effect on cancer cells, and we have discovered new chemical substances and published what for protein the drug interacts with in the cell and the mechanisms of action. Patenting is underway in collaboration with VIS and with further development in collaboration with research groups in Shanghai and the company Xennials Therapeutics in Chicago. One exciting project is cryoimmunotherapy, abbreviated CryoIT. This is a form of immunotherapy that uses the patient’s own dendritic immune cells. After parts of the cancerous tissue are killed by a freezing process with special equipment inside the patient, the immune cells are injected into the freeze-killed cancerous tissue. These dendritic cells are capable of responding to what is different in cancer cells and can then instruct the entire immune system to attack the cancer cells, including cancer cells that have spread in metastases around the body. A Phase I clinical trial has just been conducted with CryoIT for patients with metastatic prostate cancer. The results are very useful for the next generation CryoIT with start-up in 2021.
\nThe research group has received support from the Research Council’s program NFR TREATMENT and from the Cancer Society for robust production of more potent therapeutic dendritic cells for the next generation of CryoIT. The cells will be produced in the new therapeutic cell laboratory in the Helse Bergen building on the Laboratory building floor 1M. In this work, we focus on a synergy between the pharmacological screening project and CryoIT.<\/p>\n

What do you enjoy working on at K2?<\/strong><\/p>\n

It is research that is the major challenge and the biggest commitment, otherwise I would probably have gone in clinical direction with patient work at the hospital. The collaboration with the others in the group and colleagues and clinical teams is inspiring. It is also rewarding to be able to teach and disseminate to the students and to experience the many young talents that are going on with their education and goals. I feel that there is a good environment in the Laboratory building, but that the potential for research and innovation is still greater than what has manifested itself until now. We have a compact medical campus with a very well equipped laboratory. It is sad that so many colleagues lack project funding. In particular, the experimental research is underfunded as operating expenses are relatively high. I am extremely grateful for the great support that my research group has received from private heathens in Bergen. This support has been essential to ensure that our projects are progressing well, that new people are being hired, and that we are looking forward to exciting years where new cancer treatment is a key goal.[:]<\/p>\n","protected":false},"excerpt":{"rendered":"

[:no]Kan du fortelle litt om arbeidet ditt? Kva er dei konkrete arbeidsoppg\u00e5vene dine? Eg er tilsett i 100 % stilling som professor i medisinsk virologi ved Klinisk institutt 2. I tillegg er eg overlege i bistilling ved Mikrobiologisk avdeling, Haukeland…<\/p>\n

Read more →<\/a><\/p>\n","protected":false},"author":4474,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-17500","post","type-post","status-publish","format-standard","hentry","category-nyheter"],"_links":{"self":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/17500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/users\/4474"}],"replies":[{"embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=17500"}],"version-history":[{"count":9,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/17500\/revisions"}],"predecessor-version":[{"id":17518,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/posts\/17500\/revisions\/17518"}],"wp:attachment":[{"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=17500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/categories?post=17500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/k2info.w.uib.no\/en\/wp-json\/wp\/v2\/tags?post=17500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}